INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced positive patient-reported health outcomes from a Phase III clinical trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 or GLP-1 receptor agonist being studied as a once-weekly treatment for type 2 diabetes. The company said that the results will be presented at the 49th European Association for the Study of Diabetes or EASD Annual Meeting in Barcelona, Spain.
In addition to reductions in HbA1c (hemoglobin A1c) levels and weight at 26 and 52 weeks with dulaglutide 1.5 mg, dulaglutide-treated patients reported significant, positive improvements compared to baseline across several patient-reported indicators of diabetes management, measured using validated questionnaires, including: satisfaction with treatment and rates of perceived hyperglycaemia as measured by the Diabetes Treatment Satisfaction Questionnaire or DTSQ; weight-related self-perception (Impact of Weight on Self-Perception or IW-SP and Ability to Perform Physical Activities of Daily Living Questionnaires or APPADL); and perceived current health status (EuroQoL 5-Dimension Questionnaire or EQ-5D).
According to the company, the patient-reported outcomes from the AWARD-1 trial showed that treatment satisfaction, as measured by the DTSQ, was significantly higher with dulaglutide compared to baseline, and was significantly greater compared to placebo and exenatide twice-daily at 26 weeks. Significant improvements were also seen compared to baseline and exenatide twice-daily at 52 weeks.
The company stated that Clinical results from the AWARD-1 trial showed that treatment with dulaglutide 1.5 mg led to improvements in HbA1c levels and weight reductions. Dulaglutide-treated patients also demonstrated significant improvements compared to baseline and exenatide twice-daily in perceived hyperglycaemia scores (using DTSQ) at 26 and 52 weeks.
Patients in the study noted significant improvements in weight-related self-perception (IW-SP) compared to baseline at 26 weeks, which persisted through one year of treatment. These improvements were not significantly different between all treatment groups. There were no significant differences in the ability to perform physical activities of daily living (APPADL) between dulaglutide-treated patients compared to baseline, placebo or exenatide-treated patients.2
Treatment with dulaglutide, as well as with exenatide twice-daily, led to significant improvements in perceptions of current health status or EQ-5D compared to baseline at 26 weeks; these improvements with dulaglutide 1.5 mg as well as exenatide twice-daily were also significant compared to placebo. Significant improvements were also seen compared to baseline at one year, with no significant differences between dulaglutide and exenatide twice-daily.
In the clinical trial, gastrointestinal-related symptoms, including nausea, vomiting and diarrhoea, were the most common adverse events reported for dulaglutide and were mostly mild to moderate and transient.
Dulaglutide is one of several diabetes molecules in Lilly's late-stage pipeline. Lilly said it expects to submit dulaglutide to regulatory authorities in 2013.
Copyright RTT News/dpa-AFX
© 2013 AFX News
